濠亮環球(08118.HK)與東莞中尚訂立策略合作備忘錄
格隆匯2月11日丨濠亮環球(08118.HK)公吿,於2022年2月11日,公司全資附屬公司東莞市濠亮實業有限公司("濠亮實業")與東莞中尚健康生物科技有限公司("東莞中尚")訂立策略合作備忘錄,據此,訂約方將於兩年目標時限內在中華人民共和國進行開發人工中醫藥及用於家居健康管理的人工智能機械人終端系統以及研發、生產及銷售中醫藥人工智能家居服務機械人的策略合作。
集團主要從事製造及銷售優質LED燈產品,並致力研發先進技術並將其應用至智能照明產品。董事會認為,訂立備忘錄對本集團而言屬有利,原因為其將促使有關訂約方進行磋商,令訂約方能利用其各自的優勢、資源及專業知識,為開發保健技術建立穩定及互利的策略關係。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.